Talphera (NASDAQ:TLPH – Get Free Report) and Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY – Get Free Report) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, dividends, valuation, risk, earnings and institutional ownership.
Earnings & Valuation
This table compares Talphera and Shionogi & Co., Ltd. Unsponsored ADR”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Talphera | $650,000.00 | 60.19 | -$13.00 million | ($0.38) | -2.21 |
| Shionogi & Co., Ltd. Unsponsored ADR | $2.88 billion | 6.47 | $1.12 billion | $0.76 | 14.41 |
Profitability
This table compares Talphera and Shionogi & Co., Ltd. Unsponsored ADR’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Talphera | N/A | -126.50% | -61.93% |
| Shionogi & Co., Ltd. Unsponsored ADR | 41.82% | 13.70% | 12.16% |
Analyst Recommendations
This is a summary of recent ratings and recommmendations for Talphera and Shionogi & Co., Ltd. Unsponsored ADR, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Talphera | 1 | 0 | 1 | 0 | 2.00 |
| Shionogi & Co., Ltd. Unsponsored ADR | 0 | 0 | 0 | 0 | 0.00 |
Talphera currently has a consensus target price of $6.00, suggesting a potential upside of 614.80%. Given Talphera’s stronger consensus rating and higher possible upside, analysts plainly believe Talphera is more favorable than Shionogi & Co., Ltd. Unsponsored ADR.
Volatility & Risk
Talphera has a beta of 0.47, meaning that its share price is 53% less volatile than the S&P 500. Comparatively, Shionogi & Co., Ltd. Unsponsored ADR has a beta of 0.17, meaning that its share price is 83% less volatile than the S&P 500.
Institutional & Insider Ownership
37.7% of Talphera shares are held by institutional investors. Comparatively, 1.9% of Shionogi & Co., Ltd. Unsponsored ADR shares are held by institutional investors. 5.7% of Talphera shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
About Talphera
Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit. It is also developing LTX-608, an anti-inflammatory and antiviral potential for the treatment of multiple conditions, including disseminated intravascular coagulation (DIC), acute respiratory distress syndrome (ARDS), and acute pancreatitis; Fedsyra, a pre-filled ephedrine syringe; and PFS-02, a pre-filled phenylephrine syringe. The company was formerly known as AcelRx Pharmaceuticals, Inc. and changed its name to Talphera, Inc. in January 2024. The company was incorporated in 2005 and is headquartered in San Mateo, California.
About Shionogi & Co., Ltd. Unsponsored ADR
Shionogi & Co., Ltd. engages in the research, development, manufacture, and distribution of pharmaceuticals, diagnostic reagents, and medical devices in Japan. It offers Fetroja, a multidrug-resistant for gram-negative bacterial infection treatment; Cabenuva and Apretude an anti-HIV and HIV prophylactic drug; Xocova an oral COVID-19 treatment drug; Finibax a carbapenem antibiotic; Xofluza, an influenza antiviral drug; and Tivicay, an anti-HIV drug. It also develops S-872600 an influenza nasal vaccine; S-875670 anCOVID-19 nasal vaccine; S-540956 a nucleic acid adjuvant; S-554110 a nontuberculous mycobacterial infection; S-337395 for RSV infections; S-892216 for COVID-19 therapeutics; Olorofim for invasive aspergillosis; cefiderocol for aerobic gram-negative bacterial infections and infectious diseases; S-268019 a COVID-19 prophylactic vaccine; S-268019 a prophylactic vaccine for COVID-19; ensitrelvir for COVID-19 treatment and prevention; baloxavir for influenza virus infection; S-365598 for HIV infection; and S-555739 for suppressing aggravation of COVID-19. In addition, the company develops S-540956 for nucleic acid adjuvant; S-109802 for post-stroke spasticity; S-151128 for chronic pain; S-588210 and S-531011 for solid tumor; S-309309 for obesity; BPN14770 for Alzheimer’s disease and fragile X syndrome; S-588410 for bladder cancer; S-488210 for head and neck squamous cell carcinoma; S-005151 for Acute ischemic stroke and epidermolysis bullosa; Rizmoic for opioid-induced constipation; ADR-001 for decompensated liver cirrhosis; S-222611 for malignant tumor; S-812217 for depression; GRT7039 for pain associated with osteoarthritis of the knee; SDT-001 for inattentive ADHD; S-588410 for esophageal cancer; SR-0379 for cutaneous ulcer; and S-723595 for type 2 diabetes. The company was formerly known as Shionogi Shoten Co., Ltd. and changed its name to Shionogi & Co., Ltd. in 1943. Shionogi & Co., Ltd. was founded in 1878 and is headquartered in Osaka, Japan.
Receive News & Ratings for Talphera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Talphera and related companies with MarketBeat.com's FREE daily email newsletter.
